合并胎儿心脏病变的抗SSA抗体阳性孕妇的临床及实验室特征

doi:10.19723/j.issn.1671-167X.2023.06.015

摘要/Abstract

摘要：

目的: 探究合并胎儿心脏病变的抗干燥综合征相关抗原A(Sjögren’s-syndrome-related antigen A, SSA)抗体阳性孕妇的临床表现、实验室指征及药物特征。方法: 在2013年1月至2023年7月于北京大学人民医院就诊且最终确诊自身免疫病的孕妇中, 选择抗SSA抗体阳性且超声确诊胎儿心脏病变的患者作为病变组, 抗SSA抗体阳性且超声检查无胎儿心脏病变的患者作为对照组, 收集两组患者的临床、实验室及用药信息, 比较组间基线数据无差异后对其临床指标进行统计学分析。结果: 合并胎儿心脏病变的抗SSA抗体阳性患者共11例, 其中有先天性房室传导阻滞表现者共7例, 是最常见的胎儿心脏病变类型。病变组患者孕前确诊自身免疫病的比例显著低于对照组(P=0.032), 多因胎儿心脏病变首次进行相关免疫学检查。病变组患者孕期白细胞水平[(9.29±2.58)×10⁹/L vs. (7.10±1.90)×10⁹/L, t=3.052, P=0.004]、红细胞沉降率[49.50(48.00, 51.00) mm/h vs. 23.00(15.00, 30.25) mm/h, Z=-2.251, P=0.024]、IgA水平[3.46(2.30, 5.06) g/L vs. 2.13(1.77, 2.77) g/L, Z=-2.181, P=0.029]、抗核抗体(antinuclear antibody, ANA)滴度[1∶320(1∶160, 1∶320) vs. 1∶80(1∶40, 1∶160), Z=-3.022, P=0.003]显著高于对照组。组间孕期合并SSB抗体阳性的比例(37.5% vs. 7.7%, P=0.053)、羟氯喹使用剂量及起用时间差异均无统计学意义。病变组孕期使用激素的比例及剂量显著高于对照组(P＜0.05), 其中孕早期两组间差异无统计学意义, 而孕中期、孕晚期病变组激素使用剂量显著高于对照组。结论: 胎儿心脏病变是一种罕见但与抗SSA抗体阳性高度相关的胎儿畸形, 孕期白细胞、红细胞沉降率、IgA水平及ANA滴度显著升高的患者胎儿心脏病变发生的风险更高。胎儿房室传导阻滞一旦发生便难以逆转, 因此, 预防和监测的重要性高于补救治疗。

关键词: 抗SSA抗体, 先天性心脏缺损, 心脏传导阻滞, 妊娠, 危险因素

Abstract:

Objective: To investigate the clinical manifestations and laboratory indicators of anti-Sjögren's-syndrome-related antigen A (SSA) antibody associated fetal cardiac disease. Methods: Pregnant women hospitalized at Peking University People's Hospital from January 2013 to July 2023 were included. Eleven patients with anti-SSA antibody positive were eventually diagnosed with fetal cardiac di-sease. And patients with anti-SSA antibody positive without fetal cardiac disease were selected as controls. Clinical manifestations, laboratory indications and drug usage were compared between the two groups. Results: Among these 11 patients, congenital heart block was confirmed in seven, which was the most common manifestations of fetal cardiac malformation. The proportion of the patients diagnosed with autoimmune disease before pregnancy in fetal cardiac malformation group was significantly lower than that in the control group (P=0.032), while most of the patients in the fetal cardiac malformation group received immune-related examinations for the first time because of this time's fetal cardiac diagnosis. While most of the patients in the control group received routine examinations because of autoimmune diseases diagnosed before pregnancy. During pregnancy, the white blood cell level [(9.29±2.58)×10⁹/L vs. (7.10±1.90×10⁹/L, t=3.052, P=0.004], erythrocyte sedimentation rate [(49.50 (48.00, 51.00) mm/h vs. 23.00 (15.00, 30.25) mm/h, Z=-2.251, P=0.024], IgA level [3.46 (2.30, 5.06) g/L vs. 2.13 (1.77, 2.77) g/L, Z=-2.181, P=0.029], and antinuclear antibody (ANA) titers [1∶320 (1∶160, 1∶320) vs. 1∶80 (1∶40, 1∶160), Z=-3.022, P=0.003] were significantly higher in fetal cardiac malformation group than in the control group. The proportion of positive anti-SSB antibody during pregnancy did not show a statistically significant difference between the two groups (37.5% vs. 7.7%, P=0.053). There was no significant difference in hydroxychloroquine dosage and initiation time between the two groups. The dosage of prednisone in the second and third trimesters was significantly higher in the cardiac malformation group than that in the control group, but there was no significant difference in the first trimester. Conclusion: Fetal cardiac disease is rare in pregnant women with anti-SSA antibody. White blood cell, erythrocyte sedimentation rate, IgA, the titer of ANA positivity were higher in the fetal heart disease group during pregnancy. Since congenital heart block is difficult to reverse, its prevention and monitoring are more important than remedial treatment.

Key words: Anti-Sjögren's-syndrome-related antigen A antibody, Congenital heart defects, Heart block, Pregnancy, Risk factors

中图分类号:

R593.2

李宇菲,闫亚妮,靳家扬,李春,裴秋艳. 合并胎儿心脏病变的抗SSA抗体阳性孕妇的临床及实验室特征[J]. 北京大学学报（医学版）, 2023, 55(6): 1053-1057.

Yu-fei LI,Ya-ni YAN,Jia-yang JIN,Chun LI,Qiu-yan PEI. Clinical characteristics of fetal cardiac disease in patients with anti-SSA antibody positive[J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1053-1057.

图/表 3

表1

表2

表3

参考文献 25

1	Yuan T , Shuo Y , Qi L , et al. Pregnancy-related complications in systemic lupus erythematosus[J]. J Autoimmun, 2022, 132, 102864. doi: 10.1016/j.jaut.2022.102864
2	Merz WM , Fischer-Betz R , Hellwig K , et al. Pregnancy and autoimmune disease[J]. Dtsch Arztebl Int, 2022, 119 (9): 145- 156.
3	Fausta B , Camilla B , Irene MD , et al. Impact of pregnancy on progression of preclinical autoimmune disorders: A prospective cohort study[J]. Rheumatology (Oxford), 2022, 62 (9): 2971- 2978.
4	Marder W , Littlejohn EA , Somers EC . Pregnancy and autoimmune connective tissue disease[J]. Best Pract Res Clin Rheumatol, 2016, 30 (1): 63- 80. doi: 10.1016/j.berh.2016.05.002
5	Fischer-Betz R , Specker C . Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome[J]. Best Pract Res Clin Rheumatol, 2017, 31 (3): 397- 414. doi: 10.1016/j.berh.2017.09.011
6	李珊, 李明, 张旭. 19例新生儿红斑狼疮的心血管表现[J]. 广州医药, 2022, 53 (6): 48- 51.
7	Julkunen H , Eronen M . Long-term outcome of mothers of children with isolated heart block in Finland[J]. Arthritis Rheum, 2001, 44 (3): 647- 652. doi: 10.1002/1529-0131(200103)44:3<647::AID-ANR113>3.0.CO;2-I
8	Izmirly MP , Saxena A , Kim YM , et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus[J]. Circulation, 2011, 124 (18): 1927- 1935. doi: 10.1161/CIRCULATIONAHA.111.033894
9	Saxena A , Izmirly PM , Bomar RP , et al. Factors associated with long-term cardiac dysfunction in neonatal lupus[J]. Ann Rheum Dis, 2020, 79 (2): 217- 224. doi: 10.1136/annrheumdis-2019-215900
10	Habib SM , Vermeer MH . A baby with red plaques on the face and a first-degree heart block: Neonatal lupus[J]. Lancet, 2020, 396 (10260): 1432. doi: 10.1016/S0140-6736(20)32176-0
11	Wainwright B , Bhan R , Trad C , et al. Autoimmune-mediated congenital heart block[J]. Best Pract Res Clin Obstet Gynaecol, 2020, 64, 41- 51. doi: 10.1016/j.bpobgyn.2019.09.001
12	Brito-Zerón P , Izmirly PM , Ramos-Casals M , et al. The clinical spectrum of autoimmune congenital heart block[J]. Nat Rev Rheumatol, 2015, 11 (5): 301- 312. doi: 10.1038/nrrheum.2015.29
13	Aurélie A , Vijole D , Jeongsook P , et al. Anti-Ro52 monoclonal antibodies specific for amino acid 200-239, but not other Ro52 epitopes, induce congenital heart block in a rat model[J]. Ann Rheum Dis, 2012, 71 (3): 448- 454. doi: 10.1136/annrheumdis-2011-200414
14	Llanos C , Friedman DM , Saxena A , et al. Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus[J]. Rheumatology (Oxford), 2012, 51 (6): 1086- 1092. doi: 10.1093/rheumatology/ker515
15	Cuneo BF , Strasburger JF , Niksch A , et al. An expanded phenotype of maternal SSA/SSB antibody-associated fetal cardiac disease[J]. J Matern Fetal Neonatal Med, 2009, 22 (3): 233- 238. doi: 10.1080/14767050802488220
16	Tunks DR , Clowse EM , Miller GS , et al. Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents[J]. Am J Obstet Gynecol, 2013, 208 (1): 64.e1- 64.e7. doi: 10.1016/j.ajog.2012.09.020
17	Jaeggi E , Laskin C , Hamilton R , et al. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants[J]. J Am Coll Cardiol, 2010, 55 (24): 2778- 2784. doi: 10.1016/j.jacc.2010.02.042
18	Shinohara K , Miyagawa S , Fujita T , et al. Neonatal lupus erythematosus: Results of maternal corticosteroid therapy[J]. Obstet Gynecol, 1999, 93 (6): 952- 957.
19	刘蕾, 华益民, 周开宇. 新生儿狼疮综合征诊疗研究进展[J]. 中国循证儿科杂志, 2018, 13 (3): 231- 235.
20	Izmirly P , Kim M , Friedman MD , et al. Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA/Ro-positive mothers[J]. J Am Coll Cardiol, 2020, 76 (3): 292- 302. doi: 10.1016/j.jacc.2020.05.045
21	Julie B , Nathalie C , Adey B , et al. Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus[J]. Ann Rheum Dis, 2018, 77 (12): 1742- 1749. doi: 10.1136/annrheumdis-2018-213718
22	Strasburger FJ , Wacker-Gussmann A . Congenital heart block in subsequent pregnancies of SSA/Ro-positive mothers[J]. J Am Coll Cardiol, 2020, 76 (3): 303- 305. doi: 10.1016/j.jacc.2020.05.052
23	Friedman DM , Kim MY , Copel JA , et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: The PR Interval and Dexamethasone Evaluation (PRIDE) prospective study[J]. Circulation, 2008, 117 (4): 485- 493.
24	Gleicher N , Elkayam U . Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials[J]. Autoimmun Rev, 2013, 12 (11): 1039- 1045.
25	张利, 米荣, 王晓颖, 等. 静脉注射人免疫球蛋白治疗45例新生儿红斑狼疮的疗效[J]. 中国新药与临床杂志, 2023, 42 (6): 378- 382.

相关文章 15

[1]	魏慧, 张警丰, 姚中强, 赵金霞. 类风湿关节炎合并慢性病贫血患者的临床特征及相关因素[J]. 北京大学学报（医学版）, 2026, 58(2): 307-312.
[2]	赵杰, 付春, 赵秀娟, 薛海岩, 李纾, 王振洲, 朱凤雪. 胸部创伤患者在重症监护病房内发生呼吸机相关性肺炎的危险因素[J]. 北京大学学报（医学版）, 2026, 58(2): 351-358.
[3]	郭芷均, 俎明, 马超, 张贺军, 张静, 丁士刚. 同时性多发早期胃癌漏诊病灶的临床病理特征[J]. 北京大学学报（医学版）, 2026, 58(2): 410-415.
[4]	李欣艺, 赵金霞, 穆荣. 阿司匹林对系统性红斑狼疮妊娠者结局的影响[J]. 北京大学学报（医学版）, 2025, 57(6): 1074-1080.
[5]	李博闻, 张强, 孙益鑫. 儿童及青年漏斗胸患者Nuss术后发生脊柱侧弯的风险预测模型建立及验证[J]. 北京大学学报（医学版）, 2025, 57(5): 941-946.
[6]	杨小勇, 张帆, 马潞林, 刘承. 前列腺导管腺癌临床特征及腺外侵犯的影响因素[J]. 北京大学学报（医学版）, 2025, 57(5): 956-960.
[7]	刘伟, 郭稳, 过哲, 李春艳, 李云龙, 刘思奇, 张亮, 宋慧. 痛风患者放射学阴性骨侵蚀的相关危险因素[J]. 北京大学学报（医学版）, 2025, 57(4): 735-739.
[8]	陆梦溪, 刘秋萍, 周恬静, 刘晓非, 孙烨祥, 沈鹏, 林鸿波, 唐迅, 高培. 基于社区人群队列的甘油三酯-葡萄糖指数与心血管病发病和死亡的关联[J]. 北京大学学报（医学版）, 2025, 57(3): 430-435.
[9]	杨树涵, 李奕昕, 崔浩亮, 王佑新, 吴玉莹, 王明月, 杨依凡, 恩卡尔·努尔, 杨磊, 王辉. 代谢相关脂肪性肝病及其心脏代谢风险指标异常与不良妊娠结局的相关性[J]. 北京大学学报（医学版）, 2025, 57(3): 487-495.
[10]	杨龙傲, 金旭, 黄文初, 何丽华, 陈娟. 视屏作业人员视疲劳及干眼的流行病学调查[J]. 北京大学学报（医学版）, 2025, 57(3): 554-561.
[11]	卞雯, 周文君, 吴天晨, 朱培静, 陈一诺, 原鹏波, 王学举, 王颖, 魏瑗, 赵扬玉. 单绒毛膜双羊膜囊双胎妊娠双胎之一胎死宫内对妊娠结局的影响[J]. 北京大学学报（医学版）, 2025, 57(3): 592-598.
[12]	王文琼, 侯玉珂, 李春, 张学武. 系统性红斑狼疮患者不良妊娠结局的预测因素[J]. 北京大学学报（医学版）, 2025, 57(3): 599-603.
[13]	杨俊娟, 张蕾, 张龑. 妊娠合并脐尿管瘘1例[J]. 北京大学学报（医学版）, 2025, 57(2): 393-395.
[14]	郭华秋, 王哲, 杨雪, 白洁. 口腔急诊出血患者的临床特征与危险因素[J]. 北京大学学报（医学版）, 2025, 57(1): 142-147.
[15]	邓敏婷, 王楠, 夏斌, 赵玉鸣, 朱俊霞. 儿童及青少年挫入恒前牙自行再萌出的相关影响因素[J]. 北京大学学报（医学版）, 2025, 57(1): 148-153.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Parameters	Cardiac malformation (n=11)	Control (n=44)	P
Clinical feature, n(%)
History of miscarriage	5 (45.5)	22 (50.0)	> 0.999
Leukopenia during pregnancy	0	7 (15.9)	0.323
Thrombocytopenia during pregnancy	2 (18.2)	10 (22.7)	> 0.999
Diagnosis of autoimmune disease before pregnancy	6 (54.5)	38 (86.4)	0.032
Complicating disease, n(%)
Hashimoto thyroiditis	2 (18.2)	2 (4.5)	0.175
Hyperthyroidism	0	0	> 0.999
Hypothyroidism	1 (9.1)	8 (18.2)	0.669
Gestational diabetes mellitus	1 (9.1)	3 (6.8)	> 0.999
Ovarian tumor	0	2 (4.5)	> 0.999

Parameters	Cardiac malformation (n=11)	Control (n=44)	Z/t/χ²	P
WBC during pregnancy/(×10⁹/L)	9.29±2.58	7.10±1.90	3.052	0.004
PLT during pregnancy/(×10⁹/L)	202.20±79.05	171.51±56.68	1.428	0.159
ESR during pregnancy/(mm/h)	49.50 (48.00, 51.00)	23.00 (15.00, 30.25)	-2.251	0.024
IgA during pregnancy/(g/L)	3.46 (2.30, 5.06)	2.13 (1.77, 2.77)	-2.181	0.029
ANA positive during pregnancy	10/10 (100.0)	38/40 (95.0)		> 0.999
ANA titer during pregnancy	1∶320 (1∶160, 1∶320)	1∶80 (1∶40, 1∶160)	-3.022	0.003
Anti-SSB positive during pregnancy	3/8 (37.5)	3/39 (7.7)		0.053

Parameters	Cardiac malformation (n=11)	Control (n=44)	Z/t/χ²	P
HCQ
Use of HCQ during pregnancy, n(%)	10 (90.9)	35 (79.5)		0.667
Use of HCQ during the first trimester, n(%)	6 (54.5)	33 (75.0)		0.266
HCQ dose in the first trimester/mg, M (P₂₅, P₇₅)	200 (0, 200)	200 (25, 200)	-1.117	0.264
HCQ dose in the second trimester/mg, M (P₂₅, P₇₅)	200 (200, 200)	200 (100, 200)	-0.555	0.579
HCQ dose in the third trimester/mg, M (P₂₅, P₇₅)	200 (200, 200)	200 (125, 200)	-1.098	0.272
Prednisone
Use of prednisone during pregnancy, n(%)	9 (81.8)	16 (36.4)		0.015
Prednisone dose in the first trimester/mg, M (P₂₅, P₇₅)	0 (0, 10.00)	0 (0, 5.00)	-0.593	0.553
Prednisone dose in the second trimester/mg, M (P₂₅, P₇₅)	10.00 (0, 20.00)	0 (0, 5.00)	-2.924	0.003
Prednisone dose in the third trimester/mg, M (P₂₅, P₇₅)	10.00 (5.00, 26.70)	0 (0, 5.00)	-3.347	0.001